Clinical Trial Update: Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial update evaluating fosaprepitant dimeglumine for chemotherapy-induced nausea and vomiting; the study was terminated and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• fosaprepitant dimeglumine (fosaprepitant dimeglumine)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-01-30